Patents by Inventor Alexander Aronov

Alexander Aronov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic inhibitors of ERK2 and uses thereof
    Patent number: 7304061
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein A1, A2, TmR1, X, R2, R3, R9, R12, and R13 are as described in the specification. The compounds are especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: December 4, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Robin Hale, Francois Maltais, Qing Tang, Judith Straub, Alexander Aronov
  • C-MET protein kinase inhibitors
    Publication number: 20070254868
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.
    Type: Application
    Filed: March 21, 2007
    Publication date: November 1, 2007
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: David Lauffer, Robert Davies, Dean Stamos, Alexander Aronov, David Deininger, Ronald Grey, Jinwang Xu, Pan Li, Brian Ledford, Luc Farmer, Randy Bethiel, Dylan Jacobs, Kira McGinty
  • Deazapurines useful as inhibitors of Janus kinases
    Publication number: 20070207995
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: September 28, 2006
    Publication date: September 6, 2007
    Inventors: Francesco Salituro, Luc Farmer, Tiansheng Wang, Jian Wang, Randy Bethiel, Marion Wannamaker, Gabriel Martinez-Botella, John Duffy, Alexander Aronov, David Lauffer, Albert Pierce
  • Inhibitors of c-Met and uses thereof
    Publication number: 20070191369
    Abstract: The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders.
    Type: Application
    Filed: November 30, 2006
    Publication date: August 16, 2007
    Inventors: David Lauffer, Alexander Aronov, Pan Li, David Deininger, Kira McGinty, Dean Stamos, Jon Come, Michelle Stewart
  • Selective inhibitors of ERK protein kinase and uses thereof
    Publication number: 20060160807
    Abstract: Described herein are compounds that are useful as ERK2 inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including proliferative disorders such as cancer.
    Type: Application
    Filed: December 20, 2005
    Publication date: July 20, 2006
    Inventors: Alexander Aronov, Michael Hale, Francois Maltais, Gabriel Martinez-Botella, Judith Straub, Qing Tang
  • Heterocyclic inhibitors of ERK2 and uses thereof
    Publication number: 20050234059
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein A1, A2, TmR1, X, R2, R3, R9, R12, and R13 are as described in the specification. The compounds are especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.
    Type: Application
    Filed: March 10, 2005
    Publication date: October 20, 2005
    Inventors: Michael Robin Hale, Francois Maltais, Qing Tang, Judith Straub, Alexander Aronov
  • Heterocyclic inhibitors of ERK2 and uses thereof
    Publication number: 20040029857
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: 1
    Type: Application
    Filed: April 25, 2003
    Publication date: February 12, 2004
    Inventors: Michael Robin Hale, Francois Maltais, Qing Tang, Judith Straub, Alexander Aronov